Class III Medical Device Licence Pathway

1. Key takeaways

Class III devices require an MDL, and the application fee is 14,163 CAD (effective from 2026-04-01). The application must contain evidence of clinical effectiveness, and the officially listed acceptable forms are four: clinical trials, clinical reviews, meta-analyses, and reviews of real-world evidence. This is the class at which Health Canada’s evidentiary expectations step up sharply: the review examines not only whether the device works as described, but whether the clinical case for it has been assembled in a form the Agency recognises. Cost planning must also widen at this class, because the amendment regime is tiered by whether a change relates to manufacturing, and the two tiers are priced very differently.

• Class III devices require an MDL; the application fee is 14,163 CAD from 2026-04-01.
• Applications must contain clinical effectiveness evidence in one of four officially listed forms.
• Amendment fees are tiered: manufacturing-related changes and non-manufacturing significant changes are priced separately.
• Implantable products are typical Class III devices, supported by explicit Schedule 1 classification rules.
• The lead time for obtaining clinical evidence belongs inside the overall project timeline, not after it.

2. Legal basis

The table below lists the sources for the Class III pathway: the clinical effectiveness requirement and its accepted forms, the current application fee, the two-tier amendment fees, the licence provisions of the Regulations, and the official examples of Class III devices.

3. Expert insights

Insight 1: The four forms of clinical evidence are an official list, not a loose pick-any-one standard.

Health Canada’s official wording enumerates four forms of evidence. Choosing among them is a substantive decision: the choice must match the device’s risk profile, the data that already exist, and the population that can be accessed, and the rationale for the choice must be stated in the dossier. In GRZAN’s Class III projects, the clinical evidence strategy is treated as a standalone first technical work package. The reasoning is that every downstream clinical activity — data collection, literature work, analysis design — depends on which of the four forms has been selected, so making the selection early, and documenting why it fits, prevents the clinical section from being rebuilt mid-project.

Insight 2: Amendment fees are tiered by whether the change relates to manufacturing.

Under the Health Canada fee page, Class III amendments fall into two tiers: manufacturing-related changes at 4,470 CAD (changes to manufacturing processes, facilities, equipment or manufacturing quality control procedures) and non-manufacturing significant changes at 11,369 CAD. The latter is roughly 2.5 times the former, reflecting the difference in review effort. The classification of a change therefore has direct cost consequences, and the decision should not be made casually: a change management process that sorts changes by this criterion before budgeting and compliance routing will keep the amendment costs predictable and the filings correctly priced.

Insight 3: The Class III fee tier is 22 times that of Class II.

Class II is 643 CAD; Class III is 14,163 CAD. When enterprises plan the pathway and the budget, the classification conclusion should be treated as a cost variable, not as a matter settled afterwards. A device that sits near the Class II / III boundary carries a fee exposure that differs by an order of magnitude between the two outcomes, so the classification analysis belongs at the front of the business case, alongside the technical and market assessment, rather than being discovered once the dossier architecture has already been chosen.

Insight 4: Implantables are the typical Class III device.

Among Health Canada’s official examples, hip implants and shoulder joint prostheses are Class III. This is supported by an explicit rule in Schedule 1: under rule 1(3), devices that are absorbed by the body, or that usually remain in the body for at least 30 consecutive days, fall into Class III. For implantable products, the classification judgement therefore does not rest on analogy or argument — the rule names the duration threshold directly, and checking the intended dwell time of the device against that threshold settles the question in most cases.

4. Practical recommendations

• Determine the form of clinical evidence during dossier planning: select from the four officially listed forms and document the rationale for the match.
• Build the budget from the 14,163 CAD application fee, the two amendment tiers (4,470 / 11,369 CAD), and the cost of MDSAP certification.
• Classify changes in change management by whether they relate to manufacturing, and make the budget and compliance routing decisions afterwards.
• For implantable products, check the 30 consecutive days threshold in rule 1(3) of Schedule 1.
• Include the acquisition period for clinical evidence in the overall project timeline; do not schedule on the assumption that the submission can go out as soon as the dossier is written.

5. Verification checklist

• □ The classification has been confirmed as Class III and checked back against the Schedule 1 rules
• □ The form of clinical evidence (one of the four) has been selected and the rationale for the match has been documented
• □ The application fee (14,163 CAD) and both amendment tiers have been budgeted separately
• □ The MDSAP certificate is valid, with Canada included in the audit scope
• □ Change management has a classification process built on whether the change relates to manufacturing
• □ The acquisition period for clinical evidence has been incorporated into the overall project timeline

Regulatory information verified as of October 28, 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Canadian market. Our team manages Health Canada Medical Device Licence and MDEL applications, prepares risk-classified dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com